MKI67 and glioblastoma: Ability of GBM sphere generation in vitro using dissociated patient tumor samples as well as the number of CD133+/Ki67+ cells in the lesion are both prognostic markers of tumor progression and poor patient survival outcome (Pallini et al., 2008).